Nutriband Inc. (NTRB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board | 175k | -- | 1974 |
| Mr. Gareth Sheridan | Founder, CEO & Director | 175k | -- | 1990 |
| Mr. Gerald Goodman | CFO & Chief Accounting Officer | 140k | -- | 1948 |
| Dr. Alan Smith Ph.D. | COO & President of 4P Therapeutics | 159k | -- | 1966 |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer | -- | -- | 1970 |
| Mr. Michael Myer | President of Pocono Pharmaceutical | 40.6k | -- | 1985 |
| Mr. Tyler Overk | Head of Active Intelligence | -- | -- | 1984 |
Nutriband Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Corporate Governance
Upcoming Events
June 7, 2024 at 8:00 PM UTC - June 11, 2024 at 8:00 PM UTC
Nutriband Inc. Earnings Date